# PSP Omics Center of Acute to Chronic Pain Signatures

> **NIH NIH U54** · BATTELLE PACIFIC NORTHWEST LABORATORIES · 2022 · $678,601

## Abstract

PROJECT SUMMARY
Chronic pain is currently a substantial and growing health care issue worldwide, with its treatment directly
associated with opioid and non-steroidal anti-inflammatory use/abuse. Such treatment efforts however are
generally insufficient, hence efforts to understand how chronic pain evolves, specifically its conversion from an
acute pain event, can help inform upon more effective therapeutic options. Moreover, identification of molecular
signatures associated with or predictive of conversion from acute to chronic pain would provide new avenues to
prevent or attenuate such conversion. Though poorly understood, we do recognize the role of certain pathways
and physiological events in this conversion, including but not limited to neurogenic inflammatory responses,
synaptic plasticity, glial activation, and immune cell infiltration, along with their associated mediators and cell
receptor interactions. These associated signaling molecules and mediators represent a wide range of
biochemical species, i.e., proteins, lipids, metabolites, and extracellular RNAs, and there is evidence that such
molecules could provide a novel multi-molecular signature to chronic pain conversion. Thus, the overall objective
of this PNNL-Stanford-Pittsburgh Omics Data Generation Center (PSP-ODGC) is to develop and implement high
throughput omics-based assays for quantifying a broad and diverse set of molecular players associated with
acute to chronic pain conversion with the goal to develop predictive signatures as well as inform upon relevant
molecular mechanisms. To accomplish this objective, we are bringing together advanced mass spectrometry
(MS) multi-omics capabilities (Pacific Northwest National Laboratory, PNNL), genomics (Stanford Genome
Technology Center), and high throughput screening capabilities (Luminex Core at University of Pittsburgh
Medical Center, UPMC) to accurately detect and quantify a broad spectrum of prospective targets. Based upon
our extensive previous experience within similar consortium, i.e., the MoTrPAC (Molecular Transducers of
Physical Activity Consortium), we recognize the importance of the initial planning phase and the required need
for flexible assay proposals and development. Hence, we also strongly stress the flexibility in our strategy and
capabilities to adapt and meet the needs of the program. Overall we will facilitate communication and interaction
with the MCCs, CCC, and DIRC to streamline sample handling/control efforts for timely initiation of the study and
subsequent analysis. Secondly, provide the core ODGC components for the identification and quantification of
omics targets for the verification of molecular signatures of acute to chronic pain conversion using a two prong
discovery and targeted strategy, where the valid candidates will transition to the high throughput assay platforms
such as Luminex. Thirdly, integrate efforts with the DIRC in addressing the storage, flow, and format of the
quantitative analysis ...

## Key facts

- **NIH application ID:** 10459355
- **Project number:** 5U54DA049116-04
- **Recipient organization:** BATTELLE PACIFIC NORTHWEST LABORATORIES
- **Principal Investigator:** Jon Jacobs
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $678,601
- **Award type:** 5
- **Project period:** 2019-09-01 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10459355

## Citation

> US National Institutes of Health, RePORTER application 10459355, PSP Omics Center of Acute to Chronic Pain Signatures (5U54DA049116-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10459355. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*